Skip to main content

Table 3 HbA1c and fasting blood glucose (FBG) levels per treatment group at baseline and the end of the monitoring period

From: Intensification of insulin therapy in patients with type 2 diabetes: a retrospective, non- interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice

  Control group Active group p-value†
HbA1c (%)    
   Prior treatment 8.18 ± 1.33 8.53 ± 1.29  
   After treatment 7.58 ± 1.06 7.39 ± 0.81  
   p-value (baseline vs end)‡ <0.001 <0.001  
LS mean difference (95% CI) 0.53 (0.31-0.76) <0.001
FBG (mg/dl)    
   Prior treatment 168.9 ± 47.2 182.6 ± 57.1  
   After treatment 148.5 ± 42.7 135.6 ± 34.5  
   p-value(baseline vs end) ‡ <0.001 <0.001  
LS mean difference (95% CI) 27.85 (15.74-39.95) <0.001
  1. †Statistically significant difference between the control and the active group.
  2. ‡Statistically significant difference in least squares means of HbA1c in each treatment group.
  3. CI confidence intervals.
  4. LS least squares.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us